Synonyms: GSK3772701 | GSK701 | MMV1582367
Compound class:
Synthetic organic
Comment: MMV367 is an antimalarial clinical candidate, selected from a new class of pyrrolidinamide-containing compounds identified from a phenotypic screen. The chemical structure was first disclosed during the 265th National Meeting of the American Chemical Society (Boston, 2018) [4] and is one of the structures claimed in patent WO2019145360A1 [2].
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. |
|
No information available. |
Summary of Clinical Use ![]() |
MMV367 is in clinical development for the treatment of uncomplicated malaria. It has completed a first-in-human study to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers (NCT05507970). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05507970 | First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367 | Phase 1 Interventional | Medicines for Malaria Venture |